What happened
The ClinicalTrials.gov record NCT07826689 describes a planned two-part study: single doses in healthy adults, followed by monthly doses in adults with relapsing MS and chronic optic neuropathy. The 17 September 2026 posting date and study details were available through a secondary mirror attributing them to ClinicalTrials.gov; they could not be independently checked against the primary record.
What this means for people with MS
This is a research plan, not a result. Current recruitment and whether the study has started remain unconfirmed.
About the approach studied in this programme: PRO-1562
PRO-1562 is an experimental oral small molecule studied for a possible effect on myelin repair. The study measures safety, drug exposure and repair-related outcomes. Its exact molecular target is not established by the sources reviewed here; a repair effect remains a study question, not an established action.
Approach source: ClinicalTrials.gov — PRO-1562 study record ↗
- What kind of evidence exists?
- Trial description reported through a secondary registry mirror; no results available
- How reliable is this source?
- The primary record is linked but was not independently retrievable; the date and description were checked only in a secondary mirror.
- Research event/source date
- Published by MyelinWatch
- Last substantive MyelinWatch update